IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.603
-0.007 (-1.20%)
At close: Nov 20, 2024, 4:00 PM
0.591
-0.011 (-1.86%)
Pre-market: Nov 21, 2024, 7:15 AM EST
IceCure Medical Revenue
IceCure Medical had revenue of $1.01M in the quarter ending June 30, 2024, with 7.90% growth. This brings the company's revenue in the last twelve months to $3.34M, up 3.60% year-over-year. In the year 2023, IceCure Medical had annual revenue of $3.23M with 4.67% growth.
Revenue (ttm)
$3.34M
Revenue Growth
+3.60%
P/S Ratio
8.44
Revenue / Employee
$43,325
Employees
77
Market Cap
29.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | -1.87M | -32.61% |
| Dec 31, 2019 | 5.74M | 1.70M | 42.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 48.43M |
| Curis | 10.26M |
| DURECT | 8.59M |
| NeurAxis | 2.46M |
| SAB Biotherapeutics | 1.51M |
ICCM News
- 1 day ago - IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PRNewsWire
- 2 days ago - IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - PRNewsWire
- 13 days ago - FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - PRNewsWire
- 23 days ago - Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - PRNewsWire
- 4 weeks ago - IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - PRNewsWire
- 6 weeks ago - IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - PRNewsWire
- 2 months ago - IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PRNewsWire
- 2 months ago - Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - PRNewsWire